Heart and Lung Transplant in a Patient with Relapsed AL Amyloidosis

Introduction: AL amyloidosis is a systemic disease of abnormal light chain production and pathologic amyloid fibrils that infiltrate tissue and lead to organ dysfunction. Solid organ transplantation historically has played a small role in management due to concerns of multi-organ involvement and risk of relapse. Standard of care previously included cyclophosphamide, bortezomib, and dexamethasone (CyBorD). For relapsed disease, treatment options often included immunomodulatory drugs that are associated with an increased risk of transplant rejection or autologous bone marrow transplant.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research